Search
for
Sort by
Research 271–300 of 1000+
- ANTI-CANCER MEDICINS (CLASSIFICATION AND MECHANISMS OF ACTION)
- Is dehydroepiandrosterone a hormone?
- Responsive Microneedles as a New Platform for Precision Immunotherapy
- Biomedical Applications of Bee Venom: A Natural Approach to Cancer, Infections, and Inflammatory Diseases
- Analysis of androgen receptor expression and activity in the mouse brain
- Potential of nano-phytochemicals in cervical cancer therapy
- Venous thromboembolism and women's health
- Recent Development in NSCLC Immunotherapies: Mechanisms, Advantages and Research Findings
- Subacute cutaneous lupus erythematosus in a patient of pancreatic cancer secondary to novel albumin-bound paclitaxel chemotherapy
- Long-term opioid ADR management in cancer patients
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES Human serum albumin nanoparticles for enhanced drug delivery to treat breast cancer: Preparation and In Vitro assessment
- Phytotherapeutic Molecules & Antioxidants: A Novel & Secure Approach of Cancer Prevention
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Cetuximab-induced hypertrichosis of the scalp and eyelashes
- Unraveling the Role of Repurposed Drugs in the Treatment of Acne: Success so Far and the Road Ahead
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Natural bioactive compounds as potential sources for alleviation and treatment of androgenetic alopecia: A research advance
- Anthocyanin as Colorectal Anticancer: A Brief Review
- Androgen Treatment in Women
- The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
- Skin Ageing in Women: Pathophysiology and Treatment
- Pain in pancreatic cancer: A medical oncologist's view
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- American Academy of Dermatology
- Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
- Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer